asa glp 1 guidelines The 2023 position on GLP-1 receptor agonists has been overturned by three 2025 consensus statements. Continue the drug. Change the fast. ANZCA/ADS/GESA/NACOS, the Association of Anaesthetists/RCoA, and SPAQI/AACE now converge on Are Serious Anesthesia Risks of

Gentle swirling, never shaking, is the rule

Discounts greater than 14% are applied to the initial product price, exclusively online

Many patients successfully resume at lower doses or use the Microdose GLP-1 Protocol ($129/mo) for a gentler restart if they experienced side effects previously

No side effects

Pain is prevalent, often requiring analgesics, while muscle cramps affect up to 68% of patients, treated with supplements like zinc and taurine despite limited evidence

The lack of success at Phase III was attributed to factors such as high baseline immunosuppressive therapy in patients and complex disease mechanisms in SLE, potentially limiting the application of Rituximab as a monotherapy in SLE (119)